118 related articles for article (PubMed ID: 15739575)
1. Research on Parkinson disease.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
J Neurosurg; 2005 Feb; 102(2):401. PubMed ID: 15739575
[No Abstract] [Full Text] [Related]
2. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
J Neurosurg; 2005 Feb; 102(2):216-22. PubMed ID: 15739547
[TBL] [Abstract][Full Text] [Related]
3. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
Patel NK; Bunnage M; Plaha P; Svendsen CN; Heywood P; Gill SS
Ann Neurol; 2005 Feb; 57(2):298-302. PubMed ID: 15668979
[TBL] [Abstract][Full Text] [Related]
4. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
Gill SS; Patel NK; Hotton GR; O'Sullivan K; McCarter R; Bunnage M; Brooks DJ; Svendsen CN; Heywood P
Nat Med; 2003 May; 9(5):589-95. PubMed ID: 12669033
[TBL] [Abstract][Full Text] [Related]
5. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
[TBL] [Abstract][Full Text] [Related]
6. Crossroads in GDNF therapy for Parkinson's disease.
Sherer TB; Fiske BK; Svendsen CN; Lang AE; Langston JW
Mov Disord; 2006 Feb; 21(2):136-41. PubMed ID: 16470786
[TBL] [Abstract][Full Text] [Related]
7. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
[No Abstract] [Full Text] [Related]
8. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
[TBL] [Abstract][Full Text] [Related]
9. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Nutt JG
Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
[No Abstract] [Full Text] [Related]
10. Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies?
Ransmayr G; Künig G; Neubauer M; Wagner M; Bösch S; Kreczy-Kleedorfer B
Adv Neurol; 1993; 60():685-9. PubMed ID: 8420211
[No Abstract] [Full Text] [Related]
11. Motor response complications with chronic levodopa therapy.
Chase TN; Fabbrini G; Juncos JL; Mouradian MM
Adv Neurol; 1990; 53():377-81. PubMed ID: 2239478
[No Abstract] [Full Text] [Related]
12. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Nyholm D; Jansson R; Willows T; Remahl IN
Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
[No Abstract] [Full Text] [Related]
13. New treatment improves symptoms of Parkinson's disease.
Mayor S
BMJ; 2002 Apr; 324(7344):997. PubMed ID: 11976237
[No Abstract] [Full Text] [Related]
14. [Effective therapy option in the late phase of Parkinson disease: subcutaneous apomorphine].
Krankenpfl J; 2005; 43(7-10):241. PubMed ID: 16515311
[No Abstract] [Full Text] [Related]
15. Trophic factor distribution predicts functional recovery in parkinsonian monkeys.
Gash DM; Zhang Z; Ai Y; Grondin R; Coffey R; Gerhardt GA
Ann Neurol; 2005 Aug; 58(2):224-33. PubMed ID: 16049934
[TBL] [Abstract][Full Text] [Related]
16. Localized striatal delivery of GDNF as a treatment for Parkinson disease.
Kirik D; Georgievska B; Björklund A
Nat Neurosci; 2004 Feb; 7(2):105-10. PubMed ID: 14747832
[No Abstract] [Full Text] [Related]
17. Stereotyped hand clasping: an unusual tardive movement disorder.
Kaneko K; Yuasa T; Miyatake T; Tsuji S
Mov Disord; 1993 Apr; 8(2):230-1. PubMed ID: 8474498
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal study of the motor response to levodopa in Parkinson's disease.
Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
[TBL] [Abstract][Full Text] [Related]
19. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
Neurosurg Focus; 2006 May; 20(5):E1. PubMed ID: 16711657
[TBL] [Abstract][Full Text] [Related]
20. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.
Patel NK; Pavese N; Javed S; Hotton GR; Brooks DJ; Gill SS
Neurology; 2013 Sep; 81(13):1176-8. PubMed ID: 23946313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
